GLP-1 Telehealth with Insurance: What's Covered in 2026

The most common question we hear: "Will my insurance cover GLP-1 medications if I get them through telehealth?" The answer in 2026 is more complicated — and more hopeful — than it was even a year ago. Medicare coverage has expanded, employer plans are gradually adding benefits, and the landscape shifts every quarter. Here's the current state of play.

The Two Paths: Brand-Name with Insurance vs. Compounded Cash-Pay

Understanding GLP-1 telehealth insurance starts with separating two fundamentally different purchasing paths.

Path 1: Brand-name with insurance. You use a telehealth platform to get a prescription for FDA-approved Wegovy, Ozempic, or Zepbound, then fill it through your insurance pharmacy benefit. The telehealth consultation itself may or may not be covered, but the medication goes through your normal insurance formulary.

Path 2: Compounded cash-pay. You pay the telehealth platform directly for a compounded version of semaglutide or tirzepatide. Insurance is not involved at any stage — not for the consultation, not for the medication. This is the model most telehealth GLP-1 platforms use, and it's why they can offer medications at $130–200/month instead of $1,000+.

Most telehealth platforms operate on Path 2. A few — notably Sesame Care, Found Health, and Ro — straddle both paths, offering insurance navigation for brand-name products alongside cash-pay compounded options.

Commercial Insurance: Highly Variable

Coverage through employer-sponsored or individual commercial plans depends on three factors: your insurer (Aetna, UnitedHealthcare, BCBS, Cigna), your pharmacy benefit manager (CVS Caremark, Express Scripts, OptumRx), and whether your employer opted into obesity drug coverage.

The numbers are sobering. As of mid-2026, approximately 85% of commercial plans cover Ozempic for type 2 diabetes. But only about 45% cover Wegovy for obesity — and coverage rates for Zepbound are even lower. Prior authorization is required by nearly every plan, and the documentation requirements are extensive: BMI above 30 (or 27 with comorbidities), documented prior weight loss attempts, and often a requirement that you've tried lifestyle modification or other medications first.

If your plan covers GLP-1s for obesity, expect copays ranging from $25 to $200/month depending on your plan's tier structure and deductible status. If your plan doesn't cover them, you're looking at full retail: $1,300+/month for Wegovy, $1,000+/month for Zepbound.

To check your coverage: call the member services number on your insurance card and ask specifically whether your formulary covers the brand-name drug you're interested in for diagnosis code E66 (obesity). Ask about tier placement and prior authorization requirements.

Medicare: The 2026 Expansion

Medicare GLP-1 coverage has undergone a significant shift in 2026. Historically, Medicare Part D explicitly excluded medications used for weight loss. That's changing through two pathways.

The Medicare GLP-1 Bridge is a demonstration program launching July 1, 2026. Eligible beneficiaries with obesity can access Wegovy (injection and tablets), Zepbound (KwikPen), and Foundayo (newly FDA-approved) through a prior authorization process, paying a flat $50/month copay. CMS covers the remaining balance of $245/month. This is temporary — a bridge to broader coverage legislation — but it's the first time Medicare has covered GLP-1 medications specifically for weight loss.

Existing Part D coverage continues for GLP-1 medications prescribed for type 2 diabetes (Ozempic) and for Wegovy when prescribed for cardiovascular risk reduction in patients with established heart disease and obesity. These indications go through standard Part D formulary processes.

Medicare Advantage (Part C) plans may offer additional GLP-1 coverage as a supplemental benefit, but this varies by plan. Check your specific plan's evidence of coverage document.

Manufacturer Savings Programs

Both Novo Nordisk and Eli Lilly offer direct savings programs that can dramatically reduce out-of-pocket costs for brand-name medications, even without insurance coverage.

Novo Nordisk is offering Wegovy injectables at $199/month for the first two months (through June 30, 2026), with subsequent doses up to $349/month. Foundayo pills start at $149/month through December 2026.

Eli Lilly offers Zepbound KwikPens through its direct savings program, with prices ranging from $399 to $449/month depending on dose — a significant discount from the $1,000+ retail price.

These programs are available to patients paying out of pocket, regardless of insurance status. They can be combined with telehealth platforms that prescribe brand-name medications.

When Compounded Cash-Pay Wins on Cost

Even with insurance, the math doesn't always favor brand-name. If your insurance copay for Wegovy is $200/month and compounded semaglutide through telehealth is $149/month, the telehealth option is cheaper. If your plan requires step therapy (trying a less effective medication first), prior authorization appeals, or has a high specialty drug deductible, the time and effort cost of the insurance route may outweigh the financial benefit.

Compounded cash-pay through telehealth consistently beats brand-name pricing for patients without insurance coverage or with high copays. The trade-off is that you're using a non-FDA-approved compounded product from a state-licensed pharmacy rather than an FDA-approved product from the manufacturer.

Platforms That Help with Insurance

Sesame Care is the strongest option for patients pursuing insurance-covered brand-name GLP-1s through telehealth. Consultations start at $29, and the platform helps navigate prior authorization.

Found Health offers both brand-name (with insurance navigation) and compounded options, letting patients choose based on their coverage situation. With 250,000+ patients, they have significant experience with insurance workflows.

Best Cash-Pay Alternatives